Results 1 to 10 of about 18,962 (231)

Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus [PDF]

PeerJ, 2021
Accumulating evidence has suggested the importance of gut microbiota in the development of type 2 diabetes mellitus (T2DM). In the present study, 40 patients with T2DM were treated with liraglutide for 4 months. Feces samples and clinical characteristics
Junjie Shang, Fang Liu, Bing Zhang, Kunlun Dong, Man Lu, Rongfeng Jiang, Yue Xu, Le Diao, Jiangman Zhao, Hui Tang   +9 more
doaj   +2 more sources

Liraglutide; A New Hope for Obese Diabetics [PDF]

JLUMHS, 2020
OBJECTIVE: To assess the effectiveness of liraglutide in reducing weight and Glycated haemoglobin (HbA1c) in type 2 diabetic patients. METHODOLOGY: This analytical observational study was conducted at Jinnah medical college hospital Karachi Pakistan ...
Ajeet Kumar, Dileep Kumar, Salma Razzaque , Ashok Kumar , Rajesh Kumar, Muhammad Ishaq Ghauri, Mahjabeen Yaseen   +6 more
doaj   +1 more source

Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain

Pharmaceuticals, 2022
Diabetes is commonly treated with glucagon-like peptide-1 receptor (GLP-1R) agonists including liraglutide and others. However, liraglutide was found to raise plasma glucose levels in normal rats.
Chia-Chen Hsu, Juei-Tang Cheng, Ping Hao Hsu, Yingxiao Li, Kai-Chun Cheng   +4 more
doaj   +1 more source

Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism

Cells, 2022
The impairment in endothelial progenitor cell (EPC) functions results in dysregulation of vascular homeostasis and dysfunction of the endothelium under diabetic conditions.
Xiaoqing Yan, Yue Su, Xia Fan, Hui Chen, Zixian Lu, Zijuan Liu, Yingjian Li, Mei Yi, Guigui Zhang, Chunjie Gu, Kai Wang, Jiamin Wu, Da Sun, Yikai Zhang, Chi Zhang, Xiaozhen Dai, Chao Zheng   +16 more
doaj   +1 more source

Liraglutide and Exercise: A Possible Treatment for Obesity?

Obesities, 2022
(1) Background: Obesity has become an important public health problem worldwide, and its characterization as a chronic disease reflects the impact of a complex and multifactorial condition.
Ana Paula Azevêdo Macêdo, Renan Fudoli Lins Vieira, Guilherme Domingos Brisque, Gabriela Ferreira Abud, José Rodrigo Pauli   +4 more
doaj   +1 more source

Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis

Journal of Analytical Science and Technology, 2023
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog that has been utilized for the treatment of type 2 diabetes mellitus. Liraglutide at a higher dose also shows beneficial effects in weight loss, which prompted its widespread use as an anti-obesity ...
Hyeon Seok Oh, Minkyu Choi, Tae Suk Lee, Yejin An, Eun Ji Park, Tae Hwan Kim, Soyoung Shin, Beom Soo Shin   +7 more
doaj   +1 more source

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats

Pharmaceuticals, 2020
Liraglutide, an acylated analog of glucagon-like peptide 1 (GLP-1), could improve glycemic control in diabetes. Moreover, endogenous opioid peptides play a role in blood sugar regulation.
Kai-Chun Cheng, Ying-Xiao Li, Po-Chuen Shieh, Juei-Tang Cheng, Chia-Chen Hsu   +4 more
doaj   +1 more source

The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide. [PDF]

PLoS ONE, 2014
OBJECTIVE: This study explores a new, non-invasive imaging method for the specific diagnosis of insulinoma by providing an initial investigation of the use of 125I-labelled molecules of the glucagon-like peptide-1 (GLP-1) analogue liraglutide for in vivo
Jing Lv, Yu Pan, Xiao Li, Dengfeng Cheng, Shuai Liu, Hongcheng Shi, Yifan Zhang   +6 more
doaj   +1 more source

Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin

Stem Cell Research & Therapy, 2020
Background ARDS and ALI are life-threatening diseases with extremely high mortality in patients. Different sources of MSCs could mitigate the symptoms of ALI from diverse mechanisms. Liraglutide is an activator of glucagon-like peptide-1 receptor (GLP-1R)
Xiaotong Yang, Xiaoying Ma, Ocholi Don, Yuanlin Song, Xiaoyan Chen, Jianwen Liu, Jieming Qu, Yun Feng   +7 more
doaj   +1 more source

Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet

Animal Models and Experimental Medicine, 2020
Background Liraglutide, a GLP‐1 receptor agonist, has recently been used to treat metabolic syndrome (MS) because of its anti‐diabetic and anti‐obesity effects.
Noriyuki Kaji, Yoshiichi Takagi, Satomi Matsuda, Anna Takahashi, Sakurako Fujio, Fumitoshi Asai   +5 more
doaj   +1 more source